Clinical Trial Update: Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) [Phase 1]

View source ↗

Summary

This Phase 1 trial of the DT388GMCSF fusion protein in acute myeloid leukemia and chronic myelomonocytic leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• DT388GMCSF Fusion Protein (DT388 GM-CSF fusion protein)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 | Status: TERMINATED